MedTrace Logo

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

NCT04776265 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-01-09

No results posted yet for this study

Summary

This is a multicenter, observational real world study with prospective follow up that will evaluate the treatment approach in patients with relapsed/refractory cHL who undergo ASCT in Argentina.

Conditions

  • Hodgkin Lymphoma, Adult
  • Relapsed Hodgkin's Disease, Adult
  • Refractory Hodgkin Lymphoma

Interventions

OTHER

Evaluation of therapeutical approach after ASCT

Evaluation of therapeutical approach after ASCT

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Grupo Argentino de Tratamiento de la Leucemia Aguda

    lead OTHER

Principal Investigators

  • Lorena Fiad · Grupo Argentino de Tratamiento de la Leucemia Aguda

  • Florencia Negri Aranguren · Grupo Argentino de Tratamiento de la Leucemia Aguda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-03-01
Completion
2024-04-01

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04776265 on ClinicalTrials.gov